Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics Ltd.

December 18, 2014 07:26 ET

First Patients Examined with Ventripoint's Heart Analysis System in China at Shandong Provincial Hospital

SEATTLE, WASHINGTON--(Marketwired - Dec. 18, 2014) - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) is pleased to announce that it has installed its VMS™ heart analysis system at the Shandong Provincial Hospital (SPH) in Jinan, China and has examined a number of patients. The SPH does 300 cardiac ultrasound exams a day and has nine other hospitals in its group.

"The cardiologists in our hospital have been conducting research on the right ventricle for a long time and have achieved significant results in this field of study. The VMS is a convenient and valuable diagnostic tool, which allows our cardiology team to create fast and accurate reconstructions of the right ventricle", said Director Guo Wen Bin, Director of the Ultrasound Centre at SPH and also the Director of the Image and Ultrasound Association in Shandong Province. "I am very impressed that the cardiologists in our ultrasound center were able to master the VMS so quickly and obtain accurate results for the right ventricle. The quantitative medical data is very useful in diagnostics, clinical treatment, and medical research. "

"The scale of echocardiography in China is truly a wonder and their cardiologists enthusiastically embraced the ability to obtain functional information about the right heart in a few minutes using the VMS heart analysis system", said Dr. George Adams, CEO of Ventripoint. "The pioneer VMS machine in China has attracted the attention of cardiologists in hospitals and universities from different cities. The opportunity and marketplace in China is absolutely enormous and the best part is, it's untapped. Our potential revenue forecasts in China alone could easily propel our company to the next level so I am very excited to see where these prospects lead to in 2015. With such positive feedback from doctors, we are one step closer towards distributing the VMS machines throughout the country."

About Shandong Provincial Hospital (SPH)

Founded in 1897, Shandong Provincial Hospital is the largest and highest level hospital in Shandong Province with more than 5,000 doctors and staff and 3,294 beds. SPH treated 3.02 million patients in 2013 and carried out 53,000 operations. In 2014, EENT Hospital, Shandong Medical Image Institute, Shandong Maternity Hospital, Shandong Orthopedics Hospital, Shandong Children's Hospital, Shandong Stomatological Hospital, HeZe City Hospital and Dongying City Hospital were merged to form the SPH Medical Group.

About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. The VMS is the first cost-effective and accurate tool for measuring right ventricle heart function, and is approved for clinical use for selected cardiac indications in Canada and Europe, and cleared for use in adult PAH patients by the FDA in the United States. The Company has a suite of applications for all major heart diseases and imaging modalities, including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information